XML 48 R40.htm IDEA: XBRL DOCUMENT v3.25.3
Discontinued Operations - Schedule of Details of Assets and Liabilities Held-for-Sale (Details) - SomaScan Business - USD ($)
$ in Thousands
Sep. 30, 2025
Dec. 31, 2024
ASSETS    
Accounts receivable, net $ 27,623 $ 18,867
Inventory 40,760 38,520
Property, plant and equipment, net 16,480 19,781
Operating lease right-of-use assets, net 1,397 2,261
Intangible assets, net 27,239 28,954
Goodwill [1] 111,923 111,297
Other assets 5,254 6,715
Total assets held for sale 230,676 226,395
LIABILITIES    
Accounts payable 5,491 7,231
Accrued liabilities 10,647 9,307
Operating lease liabilities 1,400 2,301
Deferred revenue [2] 2,406 2,844
Other liabilities 2,270 5,900
Total liabilities $ 22,214 $ 27,583
[1] In connection with the classification of the SomaScan Business as discontinued operations, the Company allocated $111.9 million of goodwill, representing 100% of the Company's total goodwill, to the discontinued operations. The allocation was determined based on the relative fair values of the disposal group and the remaining business, consistent with guidance in ASC 350-20.
[2] As of September 30, 2025 and December 31, 2024, $29.9 million and $30.0 million, respectively, of deferred revenue related to the Collaboration Agreement was not included in the disposal group held for sale as SomaLogic's obligation to provide SOMAmer reagents under the Collaboration Agreement will be settled upon closing of the Transaction and will not be transferred to Illumina as a legal obligation. See footnote 1 under the table above for more details about the deferred revenue related to the Collaboration Agreement.